Genentech Avastin Labeling Will Reflect New Data On Thromboembolic Events
Genentech is in discussions with FDA on revisingAvastin labeling to reflect an increased risk of thromboembolic events
Genentech is in discussions with FDA on revisingAvastin labeling to reflect an increased risk of thromboembolic events